PDF(Pubmed)
Abstract：
UNASSIGNED: The administration of proton pump inhibitors (PPIs) is anticipated to elevate an individual\'s susceptibility to enteric infections as a result of altering the gut flora. The influence of PPIs on the clinical manifestation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still uncertain. This study aims to investigate the impact of PPI usage on the clinical manifestation of COVID-19, namely its gastrointestinal symptoms.
UNASSIGNED: This is a cross-sectional cohort study involving COVID-19 patients. Patients were interviewed using a predesigned questionnaire that asked about their demographics, clinical manifestations of COVID-19 infection, and the extent and type of PPIs in use. PPI usage was confirmed by reviewing patients\' electronic medical records. The primary outcome was to establish any association between the use of PPI and the symptoms and clinical presentation of COVID-19.
UNASSIGNED: Out of a total of 254 participants, 69 (27.2%) were considered PPI users. Patients who were on PPI medications reported a significantly lower rate of myalgia (27.5% vs 51.9%; p = 0.0006) and heartburn (5.7% vs 15.6%; p = 0.03) but had a significantly higher rate of abdominal pain (27.5% vs 13.5%; p = 0.001) and diarrhoea (28.9% vs 14.5%, p = 0.02) when compared to those who were not using PPIs. Patients on PPIs were also shown to have significantly higher odds of developing diarrhoea (OR 2.0, 95% CI: 1.08 to 3.93, p = 0.02) and abdominal pain (OR 2.0, 95% CI: 1.22 to 3.93, p = 0.03), but a lower risk of developing myalgia (OR 0.5, 95% CI: 0.3 to 0.9, p = 0.02) when compared to non-PPI users.
UNASSIGNED: This study shows that the use of PPIs could impact COVID-19 clinical presentation toward more gastrointestinal manifestations. Further studies investigating the link between other acid suppression medications and COVID-19 manifestations and severity should be carried out.
UNASSIGNED: This is a cross-sectional cohort study involving COVID-19 patients. Patients were interviewed using a predesigned questionnaire that asked about their demographics, clinical manifestations of COVID-19 infection, and the extent and type of PPIs in use. PPI usage was confirmed by reviewing patients\' electronic medical records. The primary outcome was to establish any association between the use of PPI and the symptoms and clinical presentation of COVID-19.
UNASSIGNED: Out of a total of 254 participants, 69 (27.2%) were considered PPI users. Patients who were on PPI medications reported a significantly lower rate of myalgia (27.5% vs 51.9%; p = 0.0006) and heartburn (5.7% vs 15.6%; p = 0.03) but had a significantly higher rate of abdominal pain (27.5% vs 13.5%; p = 0.001) and diarrhoea (28.9% vs 14.5%, p = 0.02) when compared to those who were not using PPIs. Patients on PPIs were also shown to have significantly higher odds of developing diarrhoea (OR 2.0, 95% CI: 1.08 to 3.93, p = 0.02) and abdominal pain (OR 2.0, 95% CI: 1.22 to 3.93, p = 0.03), but a lower risk of developing myalgia (OR 0.5, 95% CI: 0.3 to 0.9, p = 0.02) when compared to non-PPI users.
UNASSIGNED: This study shows that the use of PPIs could impact COVID-19 clinical presentation toward more gastrointestinal manifestations. Further studies investigating the link between other acid suppression medications and COVID-19 manifestations and severity should be carried out.
摘要：
■预计质子泵抑制剂(PPI)的给药由于改变肠道菌群而提高个体对肠道感染的易感性。PPI对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）临床表现的影响仍不确定。本研究旨在探讨PPI使用对COVID-19临床表现，即胃肠道症状的影响。
■这是一项涉及COVID-19患者的横断面队列研究。使用预先设计的问卷对患者进行访谈，询问他们的人口统计数据，COVID-19感染的临床表现，以及使用的PPI的范围和类型。PPI的使用是通过查看患者的电子病历来确认的。主要结果是确定PPI的使用与COVID-19的症状和临床表现之间的任何关联。
■在总共254名参与者中，69人（27.2%）被认为是PPI用户。使用PPI药物的患者报告肌痛（27.5％vs51.9％；p=0.0006）和胃灼热（5.7％vs15.6％；p=0.03）的发生率显着降低，但腹痛（27.5％vs13.5％；p=0.001）和腹泻（28.9％vs14.5％，与未使用PPI的人相比，p=0.02)。服用PPI的患者发生腹泻的几率也明显较高（OR2.0，95％CI：1.08至3.93，p=0.02）和腹痛（OR2.0，95％CI：1.22至3.93，p=0.03）。但与非PPI使用者相比，发生肌痛的风险较低（OR0.5，95％CI：0.3至0.9，p=0.02）。
■这项研究表明，使用PPI可能会影响COVID-19的临床表现，使其转向更多的胃肠道表现。应进一步研究其他抑酸药物与COVID-19表现和严重程度之间的联系。
■这是一项涉及COVID-19患者的横断面队列研究。使用预先设计的问卷对患者进行访谈，询问他们的人口统计数据，COVID-19感染的临床表现，以及使用的PPI的范围和类型。PPI的使用是通过查看患者的电子病历来确认的。主要结果是确定PPI的使用与COVID-19的症状和临床表现之间的任何关联。
■在总共254名参与者中，69人（27.2%）被认为是PPI用户。使用PPI药物的患者报告肌痛（27.5％vs51.9％；p=0.0006）和胃灼热（5.7％vs15.6％；p=0.03）的发生率显着降低，但腹痛（27.5％vs13.5％；p=0.001）和腹泻（28.9％vs14.5％，与未使用PPI的人相比，p=0.02)。服用PPI的患者发生腹泻的几率也明显较高（OR2.0，95％CI：1.08至3.93，p=0.02）和腹痛（OR2.0，95％CI：1.22至3.93，p=0.03）。但与非PPI使用者相比，发生肌痛的风险较低（OR0.5，95％CI：0.3至0.9，p=0.02）。
■这项研究表明，使用PPI可能会影响COVID-19的临床表现，使其转向更多的胃肠道表现。应进一步研究其他抑酸药物与COVID-19表现和严重程度之间的联系。
